<p>Telix Pharmaceuticals NASDAQ: TLX 舉辦了一場教育網絡研討會，概述了其下一代前列腺特異性膜抗原（PSMA）放射藥物策略，管理層和臨牀研究者強調了在前列腺癌治療中，患者中心化劑量和改善耐受性的重要性。</p>
<p>獲取 <strong>Telix Pharmaceuticals</strong> 的提醒：</p>
<p>本次會議由 <strong>Stewart Holmstrom</strong> 主持，他是 Telix 的企業傳播總監，參與者包括 <strong>Dr. David Cade</strong>，Telix 集團首席醫學官，以及特邀講者 <strong>Professor Louise Emmett</strong>，她是悉尼聖文森特醫院的治療學與核醫學主任，同時也是 OPTIMAL-PSMA 試驗的首席研究員。</p>
<h2>放射配體治療與 Telix 的產品組合策略</h2>
<p>Dr. Cade 回顧了放射配體治療在晚期轉移性去勢抵抗性前列腺癌（mCRPC）中的確立，指出 PSMA-617（諾華的 Pluvicto）及其 VISION 試驗結果的作用，他表示該結果顯示與傳統標準治療相比，整體生存期延長了四個月。</p>
<p>他還描述了在轉移性激素敏感性前列腺癌（mHSPC）中更早使用放射配體治療的日益關注，同時強調了在身體狀況較好的患者中觀察到的一代小分子放射配體的挑戰。Dr. Cade 表示，出現的擔憂包括唾液腺輻射暴露導致口乾和生活質量影響，以及腎臟輻射暴露可能導致長期腎損傷。</p>
<p>在此背景下，Dr. Cade 概述了 Telix 的產品組合策略，採用 “非常獨特的作用機制”，包括：</p>
<ul>
<li><strong>TLX591</strong>，一種正在進行的 3 期 <strong>ProstACT Global</strong> 試驗中研究的放射抗體藥物結合物，針對晚期 mCRPC。</li>
<li><strong>TLX597-Tx</strong>，一種二代小分子放射配體治療，Dr. Cade 表示其顯示出 “非常低的唾液腺和腎臟劑量”，同時腫瘤劑量較高，這使其適合在 mHSPC 中更早使用和劑量強化策略。</li>
</ul>
<h2>OPTIMAL-PSMA：測試劑量強化和優化</h2>
<p>Professor Emmett 介紹了 <strong>OPTIMAL-PSMA</strong> 的理論基礎和早期經驗，這是一個隨機的 2 期試驗，比較劑量強化與標準劑量。她將該試驗框架描述為解決她所稱的挫折，即常見的鑥-177 PSMA 方案是圍繞外部放射腎臟限制而非療效構建的，而整體生存期的提升難以證明。</p>
<p>Professor Emmett 表示，該試驗旨在評估早期短期強化劑量是否能夠 “在癌細胞最脆弱時攻擊它們”，隨後進行後續的 “維持治療”。她將其生物學理論描述為結合（1）輻射引起的 DNA 損傷後 PSMA 的上調和（2）在 DNA 修復完全解決之前的劑量時機，可能通過治療已經受損的細胞產生 “更深的打擊”。</p>
<p>在試驗中，患者為 mCRPC，必須已對雄激素受體通路抑制劑（ARPI）和多西他賽治療失敗，或不適合多西他賽；她指出，許多入組患者已對一或兩種化療失敗。她將該隊列描述為高負荷且經過重度預處理，指出試驗的廣泛納入標準部分是由於在澳大利亞對鑥-177 PSMA 治療的有限獲取。</p>
<h2>劑量測定和早期耐受性觀察</h2>
<p>Professor Emmett 強調了來自安全性引導隊列（前 12 名患者）的劑量測定結果，將 TLX597-Tx 與 PSMA-617 和 PSMA I&amp;T 的先前出版物進行了比較。她報告了 <strong>0.28 gray 每千兆貝可勒爾</strong> 的腎臟劑量，而參考比較中的劑量為 <strong>0.58</strong> 和 <strong>0.71</strong>，並表示淚腺和唾液腺的活性 “顯著較低”，而腫瘤活性得以維持。</p>
<p>她還描述了在接受 7.5 千兆貝可勒爾 TLX597-Tx 劑量後的序列 SPECT/CT 成像時間點，指出在注射後 120 小時，腫瘤信號仍然明亮，而唾液腺和腎臟則難以可視化，部分原因歸因於腸道排泄。</p>
<p>在安全性方面，Professor Emmett 表示迄今為止的毒性較低，包括對前 10 名接受劑量強化方案治療的患者進行的 10 周後數據安全監測委員會審查。她報告了五例 1 級貧血，兩例 1 級血小板增多症，一例 1 級口乾症和兩例 3 級淋巴細胞減少症。她補充説，在高負荷疾病中，疼痛可能在頭幾周加重，她的團隊使用疼痛規劃和地塞米松來減輕疲勞。</p>
<h2>入組更新和早期疾病的計劃（OPTIMAL-E）</h2>
<p>Professor Emmett 表示 OPTIMAL-PSMA 正在接近完成入組，目前大約 <strong>90 名中的 120 名</strong> 患者已被隨機分配，主要在悉尼聖文森特醫院的一個地點。她補充説，接受的中位劑量為四次，因為通常在此時會發生進展，她表示大約 45% 的患者在第三次劑量時已發生進展——稱這是未來努力中 “需要克服的事情”，以使患者在治療中停留更長時間。</p>
<p>展望早期 mHSPC，Professor Emmett 描述了 <strong>OPTIMAL-E</strong>，這是一個結合了強化劑量與 ARPI 和雄激素剝奪治療（ADT）的概念，隨後進行 PSMA PET 引導的適應性劑量。如果在 12 周的 PSMA PET 掃描中未發現疾病，則鑥-177 PSMA 治療將停止，而 ARPI 和 ADT 將繼續，首次確認 PSA 上升時將觸發再治療。她表示希望看到高比例的患者在關鍵時間點達到 PSA 低於 0.2 且 PSMA PET 上沒有殘餘疾病，同時保持生活質量並避免過度治療。</p>
<p>在問答環節中，Cade 博士回應了關於血液毒性和胃腸道影響的問題，表示早期劑量分佈特徵表明在包括骨髓在內的器官中，非靶向劑量較低，並且報告給獨立監測委員會的觀察到的不良事件特徵與其他小分子相比，相關的全身性副作用相對較低。</p>
<p>網絡研討會結束時，Telix 重申了其在機制、劑量策略和耐受性與疾病階段之間對齊的重要性，Emmett 教授也承認該試驗在擴大新南威爾士州患者治療獲取方面的作用。</p>
<h2>關於 Telix Pharmaceuticals NASDAQ: TLX</h2>
<p>Telix Pharmaceuticals NASDAQ: TLX 是一家臨牀階段的生物製藥公司，專注於分子靶向放射藥物的開發和商業化，以用於癌症的診斷和治療。Telix 利用在放射化學、核醫學和腫瘤學方面的專業知識，旨在通過將診斷成像劑與治療性放射性核素相結合，解決多種腫瘤類型未滿足的臨牀需求。</p>
<p>該公司的產品線涵蓋了成像和治療候選藥物。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們認為比 Telix Pharmaceuticals 更好的股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Telix Pharmaceuticals 嗎？</h2>
<p>在考慮 Telix Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Telix Pharmaceuticals 並不在名單上。</p>
<p>雖然 Telix Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Telix Pharmaceuticals 舉辦了一場網絡研討會，討論其下一代 PSMA 放射藥物策略，強調以患者為中心的給藥和耐受性。David Cade 博士強調了放射配體治療在晚期前列腺癌中的作用以及第一代療法面臨的挑戰。Louise Emmett 教授介紹了 OPTIMAL-PSMA 試驗，重點關注劑量強化以提高療效。該試驗即將完成，目前已招募 120 名患者中的 90 名，旨在改善轉移性激素敏感性前列腺癌的治療。初步結果顯示新療法在安全性和耐受性方面表現良好</p>

<p>Telix Pharmaceuticals NASDAQ: TLX hosted an educational webinar outlining its next-generation prostate-specific membrane antigen (PSMA) radiopharmaceutical strategy, with management and a clinical investigator emphasizing the need for more patient-centric dosing and improved tolerability as PSMA-targeted therapy moves earlier in prostate cancer care.</p>
<div class="lb-trans"><p>Telix Pharmaceuticals NASDAQ: TLX 舉辦了一場教育網絡研討會，概述了其下一代前列腺特異性膜抗原（PSMA）放射藥物策略，管理層和臨牀研究者強調了在前列腺癌治療中，患者中心化劑量和改善耐受性的重要性。</p>
</div><p>Get <strong>Telix Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Telix Pharmaceuticals</strong> 的提醒：</p>
</div><p>The session was moderated by <strong>Stewart Holmstrom</strong>, Telix’s Director of Corporate Communications, and featured <strong>Dr. David Cade</strong>, Telix Group Chief Medical Officer, alongside guest speaker <strong>Professor Louise Emmett</strong>, Director of Theranostics and Nuclear Medicine at St Vincent’s Hospital Sydney and Principal Investigator of the OPTIMAL-PSMA trial.</p>
<div class="lb-trans"><p>本次會議由 <strong>Stewart Holmstrom</strong> 主持，他是 Telix 的企業傳播總監，參與者包括 <strong>Dr. David Cade</strong>，Telix 集團首席醫學官，以及特邀講者 <strong>Professor Louise Emmett</strong>，她是悉尼聖文森特醫院的治療學與核醫學主任，同時也是 OPTIMAL-PSMA 試驗的首席研究員。</p>
</div><h2>Positioning radioligand therapy and Telix’s portfolio approach</h2>
<div class="lb-trans"><h2>放射配體治療與 Telix 的產品組合策略</h2>
</div><p>Dr. Cade reviewed how radioligand therapy has established itself in advanced metastatic castration-resistant prostate cancer (mCRPC), pointing to the role of PSMA-617 (Novartis’ Pluvicto) and its VISION trial results, which he said showed a four-month overall survival extension compared with conventional standard of care.</p>
<div class="lb-trans"><p>Dr. Cade 回顧了放射配體治療在晚期轉移性去勢抵抗性前列腺癌（mCRPC）中的確立，指出 PSMA-617（諾華的 Pluvicto）及其 VISION 試驗結果的作用，他表示該結果顯示與傳統標準治療相比，整體生存期延長了四個月。</p>
</div><p>He also described growing interest in deploying radioligand therapy earlier, in metastatic hormone-sensitive prostate cancer (mHSPC), while highlighting challenges observed with first-generation small-molecule radioligands in fitter patients. Dr. Cade said emerging concerns include salivary gland radiation exposure leading to dry mouth and quality-of-life impacts, as well as kidney radiation exposure that could contribute to long-term renal injury.</p>
<div class="lb-trans"><p>他還描述了在轉移性激素敏感性前列腺癌（mHSPC）中更早使用放射配體治療的日益關注，同時強調了在身體狀況較好的患者中觀察到的一代小分子放射配體的挑戰。Dr. Cade 表示，出現的擔憂包括唾液腺輻射暴露導致口乾和生活質量影響，以及腎臟輻射暴露可能導致長期腎損傷。</p>
</div><p>Against that backdrop, Dr. Cade outlined Telix’s portfolio strategy using “very distinct mechanisms of action,” including:</p>
<div class="lb-trans"><p>在此背景下，Dr. Cade 概述了 Telix 的產品組合策略，採用 “非常獨特的作用機制”，包括：</p>
</div><ul>
<li><strong>TLX591</strong>, a radioantibody-drug conjugate being studied in advanced mCRPC in the ongoing Phase 3 <strong>ProstACT Global</strong> trial.</li>
<li><strong>TLX597-Tx</strong>, a second-generation small-molecule radioligand therapy that Dr. Cade said has shown “very minimal salivary gland and kidney dose” alongside a high tumor dose, which he said could make it suitable for earlier use in mHSPC and for dose intensification strategies.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>TLX591</strong>，一種正在進行的 3 期 <strong>ProstACT Global</strong> 試驗中研究的放射抗體藥物結合物，針對晚期 mCRPC。</li>
<li><strong>TLX597-Tx</strong>，一種二代小分子放射配體治療，Dr. Cade 表示其顯示出 “非常低的唾液腺和腎臟劑量”，同時腫瘤劑量較高，這使其適合在 mHSPC 中更早使用和劑量強化策略。</li>
</ul>
</div><h2>OPTIMAL-PSMA: testing dose intensification and optimization</h2>
<div class="lb-trans"><h2>OPTIMAL-PSMA：測試劑量強化和優化</h2>
</div><p>Professor Emmett presented the rationale and early experience from <strong>OPTIMAL-PSMA</strong>, a randomized Phase 2 trial comparing dose intensification versus standard dosing. She framed the trial as an effort to address what she described as frustration that common Lutetium-177 PSMA schedules were built around external beam kidney constraints rather than efficacy, while overall survival gains have been difficult to demonstrate.</p>
<div class="lb-trans"><p>Professor Emmett 介紹了 <strong>OPTIMAL-PSMA</strong> 的理論基礎和早期經驗，這是一個隨機的 2 期試驗，比較劑量強化與標準劑量。她將該試驗框架描述為解決她所稱的挫折，即常見的鑥-177 PSMA 方案是圍繞外部放射腎臟限制而非療效構建的，而整體生存期的提升難以證明。</p>
</div><p>Professor Emmett said the trial is designed to evaluate whether short, intensified dosing early can “attack the cancer cells when they're most vulnerable,” followed by later “maintenance.” She described the underlying biological thesis as combining (1) PSMA upregulation following radiation-induced DNA damage and (2) timing doses before DNA repair has fully resolved, potentially producing a “deeper hit” by treating already damaged cells.</p>
<div class="lb-trans"><p>Professor Emmett 表示，該試驗旨在評估早期短期強化劑量是否能夠 “在癌細胞最脆弱時攻擊它們”，隨後進行後續的 “維持治療”。她將其生物學理論描述為結合（1）輻射引起的 DNA 損傷後 PSMA 的上調和（2）在 DNA 修復完全解決之前的劑量時機，可能通過治療已經受損的細胞產生 “更深的打擊”。</p>
</div><p>In the trial, patients have mCRPC and must have failed an androgen receptor pathway inhibitor (ARPI) and failed docetaxel or be docetaxel-ineligible; she noted many enrolled patients have failed one or two lines of chemotherapy. She described the cohort as high-volume and heavily pre-treated, noting the trial’s broad inclusion criteria were partly driven by limited access to Lutetium-177 PSMA therapy in Australia.</p>
<div class="lb-trans"><p>在試驗中，患者為 mCRPC，必須已對雄激素受體通路抑制劑（ARPI）和多西他賽治療失敗，或不適合多西他賽；她指出，許多入組患者已對一或兩種化療失敗。她將該隊列描述為高負荷且經過重度預處理，指出試驗的廣泛納入標準部分是由於在澳大利亞對鑥-177 PSMA 治療的有限獲取。</p>
</div><h2>Dosimetry and early tolerability observations</h2>
<div class="lb-trans"><h2>劑量測定和早期耐受性觀察</h2>
</div><p>Professor Emmett highlighted dosimetry findings from the safety lead-in cohort (the first 12 patients), comparing TLX597-Tx with prior publications for PSMA-617 and PSMA I&amp;T. She reported a kidney dose of <strong>0.28 gray per gigabecquerel</strong>, compared with <strong>0.58</strong> and <strong>0.71</strong> in the referenced comparators, and said lacrimal and salivary gland activity was “significantly lower” while tumoral activity was maintained.</p>
<div class="lb-trans"><p>Professor Emmett 強調了來自安全性引導隊列（前 12 名患者）的劑量測定結果，將 TLX597-Tx 與 PSMA-617 和 PSMA I&amp;T 的先前出版物進行了比較。她報告了 <strong>0.28 gray 每千兆貝可勒爾</strong> 的腎臟劑量，而參考比較中的劑量為 <strong>0.58</strong> 和 <strong>0.71</strong>，並表示淚腺和唾液腺的活性 “顯著較低”，而腫瘤活性得以維持。</p>
</div><p>She also described serial SPECT/CT imaging timepoints after a 7.5 gigabecquerel dose of TLX597-Tx, noting that by 120 hours post-injection, tumor signal remained bright while salivary glands and kidneys were difficult to visualize, attributing part of the profile to bowel excretion.</p>
<div class="lb-trans"><p>她還描述了在接受 7.5 千兆貝可勒爾 TLX597-Tx 劑量後的序列 SPECT/CT 成像時間點，指出在注射後 120 小時，腫瘤信號仍然明亮，而唾液腺和腎臟則難以可視化，部分原因歸因於腸道排泄。</p>
</div><p>On safety, Professor Emmett said toxicity to date has been low, including a data safety monitoring board review (after 10 weeks) of the first 10 patients treated with a dose-intensified regimen. She reported five grade 1 anemias, two grade 1 thrombocythemias, one grade 1 xerostomia, and two grade 3 lymphopenias. She added that in high-volume disease, pain can worsen in the first couple of weeks, and her team uses pain planning and dexamethasone to mitigate fatigue.</p>
<div class="lb-trans"><p>在安全性方面，Professor Emmett 表示迄今為止的毒性較低，包括對前 10 名接受劑量強化方案治療的患者進行的 10 周後數據安全監測委員會審查。她報告了五例 1 級貧血，兩例 1 級血小板增多症，一例 1 級口乾症和兩例 3 級淋巴細胞減少症。她補充説，在高負荷疾病中，疼痛可能在頭幾周加重，她的團隊使用疼痛規劃和地塞米松來減輕疲勞。</p>
</div><h2>Enrollment update and plans for earlier disease (OPTIMAL-E)</h2>
<div class="lb-trans"><h2>入組更新和早期疾病的計劃（OPTIMAL-E）</h2>
</div><p>Professor Emmett said OPTIMAL-PSMA was approaching completion of enrollment, with roughly <strong>90 of 120</strong> patients randomized, largely at a single site at St Vincent’s Hospital Sydney. She added that the median number of doses received was four because progression commonly occurred around that time, and she said about 45% of patients had progressed by dose three—calling that “the thing to beat” in future efforts to keep patients on therapy longer.</p>
<div class="lb-trans"><p>Professor Emmett 表示 OPTIMAL-PSMA 正在接近完成入組，目前大約 <strong>90 名中的 120 名</strong> 患者已被隨機分配，主要在悉尼聖文森特醫院的一個地點。她補充説，接受的中位劑量為四次，因為通常在此時會發生進展，她表示大約 45% 的患者在第三次劑量時已發生進展——稱這是未來努力中 “需要克服的事情”，以使患者在治療中停留更長時間。</p>
</div><p>Looking to earlier mHSPC, Professor Emmett described <strong>OPTIMAL-E</strong>, a concept using intensive dosing up front combined with ARPI and androgen deprivation therapy (ADT), followed by PSMA PET-guided adaptive dosing. If disease is absent on a 12-week PSMA PET scan, Lutetium-177 PSMA therapy would stop while ARPI and ADT continue, with retreatment triggered at first confirmed PSA rise. She said she would like to see a high proportion of patients reaching a PSA below 0.2 and no residual disease on PSMA PET at key timepoints, while maintaining quality of life and avoiding overtreatment.</p>
<div class="lb-trans"><p>展望早期 mHSPC，Professor Emmett 描述了 <strong>OPTIMAL-E</strong>，這是一個結合了強化劑量與 ARPI 和雄激素剝奪治療（ADT）的概念，隨後進行 PSMA PET 引導的適應性劑量。如果在 12 周的 PSMA PET 掃描中未發現疾病，則鑥-177 PSMA 治療將停止，而 ARPI 和 ADT 將繼續，首次確認 PSA 上升時將觸發再治療。她表示希望看到高比例的患者在關鍵時間點達到 PSA 低於 0.2 且 PSMA PET 上沒有殘餘疾病，同時保持生活質量並避免過度治療。</p>
</div><p>During Q&amp;A, Dr. Cade responded to questions on hematologic toxicity and gastrointestinal effects, saying the early dosimetry profile suggests low off-target dose in organs including bone marrow and that the observed adverse-event profile reported to the independent monitoring committee included relatively low constitutional side effects compared with other small molecules.</p>
<div class="lb-trans"><p>在問答環節中，Cade 博士回應了關於血液毒性和胃腸道影響的問題，表示早期劑量分佈特徵表明在包括骨髓在內的器官中，非靶向劑量較低，並且報告給獨立監測委員會的觀察到的不良事件特徵與其他小分子相比，相關的全身性副作用相對較低。</p>
</div><p>The webinar concluded with Telix reiterating its emphasis on aligning mechanism, dosing strategy, and tolerability with disease stage, and with Professor Emmett acknowledging the trial’s role in expanding treatment access for patients across New South Wales.</p>
<div class="lb-trans"><p>網絡研討會結束時，Telix 重申了其在機制、劑量策略和耐受性與疾病階段之間對齊的重要性，Emmett 教授也承認該試驗在擴大新南威爾士州患者治療獲取方面的作用。</p>
</div><h2>About Telix Pharmaceuticals NASDAQ: TLX</h2>
<div class="lb-trans"><h2>關於 Telix Pharmaceuticals NASDAQ: TLX</h2>
</div><p>Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.</p>
<div class="lb-trans"><p>Telix Pharmaceuticals NASDAQ: TLX 是一家臨牀階段的生物製藥公司，專注於分子靶向放射藥物的開發和商業化，以用於癌症的診斷和治療。Telix 利用在放射化學、核醫學和腫瘤學方面的專業知識，旨在通過將診斷成像劑與治療性放射性核素相結合，解決多種腫瘤類型未滿足的臨牀需求。</p>
</div><p>The company’s pipeline spans both imaging and therapeutic candidates.</p>
<div class="lb-trans"><p>該公司的產品線涵蓋了成像和治療候選藥物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Telix Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Telix Pharmaceuticals 更好的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Telix Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Telix Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Telix Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Telix Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Telix Pharmaceuticals 並不在名單上。</p>
</div><p>While Telix Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Telix Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Telix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears End

Market Beat

Telix Pharmaceuticals 網絡研討會重點介紹下一代 PSMA 療法，OPTIMAL-PSMA 的招募工作接近尾聲